

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---------------------------------------------------------------------------------------------------------------------------------------|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/501,102-Conf. #3404 |
| | | | | Filing Date | February 9, 2000 |
| | | | | First Named Inventor | Beatriz M. Carreno |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | P. Gambel |
| Sheet | 1 | of | 3 | Attorney Docket Number | WYS-004.01 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|------------------------------------------|--------------------------------|-------------------------------------------------|---------------------------------------------------------------------------|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| 10 | AA* | US-5,397,703 | 03-14-1995 | De Boer et al. | |
| | AB* | US-5,562,903 | 10-08-1996 | Co et al. | |
| | AC* | US-5,622,701 | 04-22-1997 | Berg | |
| | AD* | US-5,869,050 | 02-09-1999 | de Boer et al. | |
| | AE* | US-5,919,449 | 07-06-1999 | Dinsmore | |
| | AF* | US-5,977,318 | 11-02-1999 | Linsley et al. | |
| | AG* | US-6,084,067 | 07-04-2000 | Freeman et al. | |
| | AH* | US-6,096,537 | 08-01-2000 | Chappel | |
| | AI* | US-6,130,316 | 10-10-2000 | Freeman et al. | |
| | AJ* | US-6,346,248 | 02-12-2002 | De Boer et al. | |
| 10 | AK* | US-6,608,180-A1 | 08-19-2003 | Sharpe et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|-----------------------------------------------------------------------------------|--------------------------------|-------------------------------------------------|---------------------------------------------------------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | |
| M | BA | WO 94/01547 | 01-20-1994 | | |
| | BB | WO 95/34320 | 12/1995 | | |
| | BC | WO 98/19706 | 05-14-1998 | | |
| | BD | WO 00/19706 | 04-06-2000 | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov/patents/branch/ptol/ptol.htm or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| M | CA | Azuma et al., "B70 antigen is a second ligand for CTLA-2 and CD28," Nature, 366:76-79 (1993) | |
| | CB | Berzofsky et al., "Antigen-Antibody Interaction," In Fundamental Immunology, W.E. Paul eds. (NY: Raven Press), pp. 595-644 (1984) | |
| | CC | Bluestone, J.A., "Costimulation and its role in organ transplantation," Clinical Transplantation, 10:104-109 (1996) | |
| | CD | Chen et al., "Costimulation of Antitumor Immunity by the B7 Counter receptor for the T Lymphocyte Molecules CD28 and CTLA-4," Cell, 71:1093-1102 (1992) | |
| | CE | Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," The J. of Immunology, 148(4):1149-1154 (1992) | |
| | CF | Cromwell et al., Abstract: "The Human PBMC-Reconstituted Nod-Scid Mouse as model of Superantigen-Induced Human T Cell Activation," Experimental Biology 98 Meeting, April 22, 1998 | |

| | | | |
|--------------------|------------------|-----------------|--|
| Examiner Signature | <i>P. Gambel</i> | Date Considered | |
|--------------------|------------------|-----------------|--|

6/18/07


| | | | | |
|---------------------------------------------------------------------------------------------------|---|----|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 09/501,102-Conf. #3404 |
| | | | Filing Date | February 9, 2000 |
| | | | First Named Inventor | Beatriz M. Carreno |
| | | | Art Unit | 1644 |
| | | | Examiner Name | P. Gambel |
| | | | Attorney Docket Number | WYS-004.01 |
| Sheet | 2 | of | 3 | |

| | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| CG | Daikh et al., "The CD28-B7 costimulatory pathway and its role in autoimmune disease," J. of Leukocyte Biol., 62:156-162 (1997) | |
| CH | Damico et al., "Pharmacokinetics of IV Administered Murine Anti-Human B7.1 and Murine Anti-Human B7.2 in Cynomolgus Monkeys," Abstract, 17th Annual Scientific Meeting, January 9, 1998 | |
| CI | Engel et al., "The B7-2 (B70) Costimulatory Molecule Expressed by Monocytes and Activated B Lymphocytes is the CD86 Differentiation antigen," Blood, 84(5):1402-1407 (1994) | |
| CJ | Fleischer et al., "Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes," Immunology, 89:592-598 (1996) | |
| CK | Fujihara et al., "Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B Irradiation: Its Involvement in Inactivation of Allogeneicity," Blood 87(6):2386-2393 (1996) | |
| CL | Glaser et al., "Dissection of the Combining Site in a Humanized Anti-Tac Antibody," The J. of Immunology, 149(8):2607-2614 (1992) | |
| CM | Goldberg et al., "Pretreatment of renal transplants with anti-CD45 antibodies: optimization of perfusion technique," Transplant Immunology, 2:27-34 (1994) | |
| CN | Harlow and Lane (Eds) Antibodies: A Laboratory Manual, Coldspring Harbor Laboratory 1988, pp. 23-35. | |
| CO | Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-907 (1993) | |
| CP | Jeannin et al., "CD86 (B7-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997) | |
| CQ | Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, Edgbaston, Birmingham, pp. 115-126 | |
| CR | Levitt, M., "Molecular Dynamics of Native Protein," J. Mol. Biol., 168:595-620 (1983) | |
| CS | Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810 | |
| CT | Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997) | |
| CU | Morrison et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993) | |
| CV | NCBI Printout, Ig gamma-2 chain C region sequence, Accession #P01859, GO121042 (July 21, 1986) | |
| CW | Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997) | |
| CX | Reiser et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996) | |
| CY | Rugtveit et al., "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997) | |
| CZ | Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999) | |
| CA1 | Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992) | |
| CB1 | Townsend et al., "Tumor Rejection After Direct Costimulation of CD8 ⁺ T Cells by B7-Transfected Melanoma Cells," Science, 259:368-369 (1993) | |

| | | | |
|--------------------|----------------------|-----------------|--|
| Examiner Signature | <i>PHILIP GAMBEL</i> | Date Considered | |
|--------------------|----------------------|-----------------|--|

6/18/07

| | | | | | |
|----------------------------------------------------------------------------------------------------------|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 09/501,102-Conf. #3404 |
| | | | | Filing Date | February 9, 2000 |
| | | | | First Named Inventor | Beatriz M. Carreno |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | P. Gambel |
| Sheet | 3 | of | 3 | Attorney Docket Number | WYS-004.01 |

| | | | |
|-----------------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
|  | CC-1 | Yokozeki et al., "Functional CD86 (B7-B70) on Cultured Human Langerhans Cells," The Society for Investigative Dermatology, Inc., 106:147-153 (1996) | <input type="checkbox"/> |
|-----------------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

P. Gambel
6/18/07

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|